ARISTOCRAT: A randomised controlled phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma

ARISTOCRAT is a UK trial testing the use of the cannabis-based drug Sativex with the current chemotherapy treatment in treating patients with recurrent glioblastoma.

The trial is led by Professor Susan Short (Chief Investigator) at University of Leeds, in collaboration with CRCTU at the University of Birmingham and is funded by The Brain Tumour Charity and sponsored by the University of Birmingham.


Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating doctor to discuss trials for which they may be eligible.


Contact us

ARISTOCRAT Trial Office,
Cancer Research UK Clinical Trials Unit (CRCTU),
Institute of Cancer and Genomic Sciences,
University of Birmingham,
Edgbaston, Birmingham
B15 2TT 


Also in 'Aristocrat'